Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10795325 | 0.84 | HTR3A (0.55) | DDB1CRBNHTR3ASLC6A4CYP1A2 | |
| SCHEMBL10797387 | 0.81 | HTR3A (0.51) | DDB1CRBNHTR3ASLC6A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL10799690 | 0.80 | HTR3A (0.50) | DDB1CRBNHTR3ASLC6A4CYP2D6 | |
| SCHEMBL2657671 | 0.79 | CRBN (0.47) | DDB1CRBNHTR3AMAPTALDH1A1 | |
| SCHEMBL2795867 | 0.79 | CYP1A2 (0.49) | DDB1CRBNHTR3ASLC6A4MAPT | |
| SCHEMBL24111487 | 0.78 | CYP2A6 (0.35) | CRBN | |
| SCHEMBL28157888 | 0.78 | CRBN (0.43) | DDB1CRBNMAPTALDH1A1CHRNB2 | |
| SCHEMBL16434776 | 0.78 | CRBN (0.43) | DDB1CRBNHTR3ACHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7476351 | 0.78 | CYP1A2 (0.47) | DDB1CRBNHTR3ASLC6A4MAPT | |
| SCHEMBL15212244 | 0.77 | DDB1 (0.39) | DDB1CRBNHTR3AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
| EP-1663966-A1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026113-A1 | 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | DDB1 2253/4885CRBN 416/4885HTR3A 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.